In a region where obesity has long pressed against the limits of available treatment, Saudi Arabia's drug authority has approved Foundaio — the first once-daily oral GLP-1 medication cleared for use in the Kingdom. The approval marks a quiet but meaningful turn in how modern medicine delivers one of its most sought-after therapies: not by needle, but by pill. Clinical evidence from nearly five thousand trial participants suggests the drug can meaningfully reduce body weight, though regulators are clear that it works best as a companion to changed habits, not a replacement for them.